NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings (NASDAQ: NTHI) appointed Ali Alabedin, Head of Islamic Banking at First Abu Dhabi Bank, to its board. Alabedin's experience in international banking may aid NeOnc's brain-cancer drug development and expansion in the UAE. NeOnc has secured UAE authorizations for its lead candidates, NEO100 and NEO212, and is preparing for an FDA meeting on November 17.
NeOnc Technologies (NASDAQ:NTHI) appointed Ali Alabedin to its board, strengthening financial and international expertise. The company's NEO212 drug received investigational new drug authorization in Abu Dhabi, subject to ethics approvals. NeOnc also reported positive Phase 2a results for NEO100 and plans an FDA meeting in November. The company is advancing treatments for brain cancer and other challenging cancers.
NeOnc Technologies Holdings reported encouraging survival data for its NEO100 treatment in a Phase 2a study of recurrent brain cancer, with a median overall survival of 26.09 months. Revolution Medicines' Rasonque received FDA approval for pancreatic cancer, showing a median overall survival of 13.2 months.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NTHI (NEONC TECHNOLOGIES HOLDINGS, INC.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent NTHI coverage spans financial news, regulation and insider activity.
In the last 30 days, NTHI insiders filed 2 SEC Form 4 transactions — 1 purchase ($115K) and 1 sale ($17K). The most active reporter was Heshmatpour Amir F, CEO, President, with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Board addition may improve financing strategy and investor confidence.
The new board member adds financial expertise and may improve investor confidence; trial progress could boost valuation if data remain positive.
Positive early survival signal may boost stock sentiment.
Upcoming FDA interaction could de‑risk the program and attract speculative buying.
The upcoming FDA meeting introduces uncertainty on trial design and regulatory path, likely keeping the stock volatile ahead of the date.
AlphAI scores every news story that mentions NTHI with an AI model for sentiment and relevance, and aggregates insider trades from NEONC TECHNOLOGIES HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NeOnc Technologies Holdings (NASDAQ: NTHI) appointed Ali Alabedin, Head of Islamic Banking at First Abu Dhabi Bank, to its board. Alabedin's experience in international banking may aid NeOnc's brain-cancer drug development and expansion in the UAE. NeOnc has secured UAE authorizations for its lead candidates, NEO100 and NEO212, and is preparing for an FDA meeting on November 17.
2 min readNeOnc Technologies (NASDAQ:NTHI) appointed Ali Alabedin to its board, strengthening financial and international expertise. The company's NEO212 drug received investigational new drug authorization in Abu Dhabi, subject to ethics approvals. NeOnc also reported positive Phase 2a results for NEO100 and plans an FDA meeting in November. The company is advancing treatments for brain cancer and other challenging cancers.
2 min readNeOnc Technologies Holdings reported encouraging survival data for its NEO100 treatment in a Phase 2a study of recurrent brain cancer, with a median overall survival of 26.09 months. Revolution Medicines' Rasonque received FDA approval for pancreatic cancer, showing a median overall survival of 13.2 months.
3 min readBiotech stocks SLXN, SMMT, IOVA, NTHI rose on Sept 29, 2026, due to positive developments. SLXN surged 30% after preclinical data. SMMT gained 6% from AstraZeneca's $2.0B investment. IOVA rose 34% on raised revenue guidance. NTHI increased 7.59% ahead of FDA meeting.
2 min readNEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 November 17 meeting will address Phase 2 study design and potential regulatory pathways CALABASAS, Calif., Sept. 28, 2026 – NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”),
2 min readNeOnc Technologies (NTHI) will meet with the FDA on November 17, 2026, to discuss its NEO212 clinical development program for CNS cancers. The company seeks feedback on trial design, endpoints, and potential accelerated approval. NEO212 showed encouraging clinical activity in Phase 1, including tumor size reduction and prolonged disease control in some patients. The FDA previously authorized Phase 2a and 2b trials.
2 min readAnalysts made several rating changes and price target adjustments. JPMorgan upgraded CoreWeave, Welltower, and Macerich, while Citi downgraded Dropbox. Bernstein upgraded Quanta Services, and Morgan Stanley initiated Imax and Nvidia with overweight ratings. Other notable moves include upgrades for Arcturus Therapeutics, Dollar General, and The Brink's Company, and initiations for NeOnc Technologies, Energy Services of America, BayCom, Avidbank, and SpaceX.
3 min readNEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution Cash redemption simplifies the capital structure with no common shares issued in the redemption CALABASAS, Calif., Sept. 17, 2026 – NeOnc Technol
1 min readHeshmatpour Amir F (CEO, President) purchased 50,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.50 ($3.30–$3.96, $0.17M total) across 2 trades over 2026-09-14 to 2026-09-15.
1 min readCHEN THOMAS C (CEO) purchased 10,798 indirectly-held shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.70 ($3.60–$3.82) across 2 trades over 2026-09-11 to 2026-09-14.
1 min read
